<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Ophthalmology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9D7015D3-F2EE-429B-8EC5-D42600C6391B"><gtr:id>9D7015D3-F2EE-429B-8EC5-D42600C6391B</gtr:id><gtr:firstName>Maryse</gtr:firstName><gtr:surname>Bailly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8B460BB-2C6E-41DD-B963-764DFE9F5171"><gtr:id>B8B460BB-2C6E-41DD-B963-764DFE9F5171</gtr:id><gtr:firstName>Peng Tee</gtr:firstName><gtr:surname>Khaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801049"><gtr:id>33FBBB5C-0EDF-4A82-ABF1-6726889AEA59</gtr:id><gtr:title>Combined in vitro and ex-vivo model to design novel combinatorial strategies for the modulation of scarring</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801049</gtr:grantReference><gtr:abstractText>Tissue contraction and scarring processes play a part in the cause or failure of treatment of virtually every major blinding disease including glaucoma, cataract, macular degeneration, and diabetes. Everyone over 60 will be affected in part by one of these conditions.Our recently completed Medical Research Council trial of glaucoma surgery has shown that in patients whose ocular scarring is well controlled, not one patient got worse over nearly a decade. There are no licenced treaments for skin and other scarring which is also a big problem. The current used anti-scarring treatments are primarily anti-cancer drugs, which may have potentially blinding side effects, and our research has shown that the models currently available to study tissue contraction and identify new promising treatments are not mimicking accurately what happens in humans. Our work in the lab has identified two previously unknown phases in tissue contraction, suggesting that better treatments should include combinations of treatments targeting both phases of the contraction process. Such an approach has been very successful in cancer chemotherapy, where single agents result in a low success rate but combinations of agents have led to some cancers being curable in the majority of cases. This project aims at further developing and validating our 2-phase model of tissue scarring using both cells and intact ocular tissue fragments maintained in culture in the lab. This project will not only generate tremendous insights into the mechanisms of contraction in the eye, but should provide us with a novel more physiologically relevant tissue contraction model to design novel strategies to modulate scarring, that could directly benefit patients in the short term. This should allow us a more rational approach to devise new treatment combinations for preventing scarring, as well as limiting the amount of animal work required before we can use these treatments to help people and prevent blinding and disabling scarring.</gtr:abstractText><gtr:technicalSummary>Tissue contraction and scarring processes play a part in the pathogenesis or failure of treatment of virtually every major blinding disease, and indeed our recently completed MRC trial of glaucoma surgery has shown that if scarring is well controlled no patient progressed over nearly a decade. Using a basic in vitro model of matrix contraction combined with an in vivo model of scarring in the rabbit, our lab has been previously successful in identifying anti-mitotic agents as potential modulators of scarring and in bringing them to the clinic. However, these treatments carry significant and potentially blinding side effects. Furthermore, the disappointing results in early clinical trials of a promising novel anti-scarring agent developed through the same models, as well as our most recent work on the basic biology of the in vitro model, suggest the need for better, more comprehensive models for the study of tissue contraction and scarring and the development of potential treatments. We have now uncovered two previously unknown distinct phases in tissue contraction, and shown that both of them need to be inactivated to achieve complete inhibition of matrix contraction. Cell protrusive activity through acto-myosin dynamics mediates the first phase of contraction, while matrix degradation and remodelling through matrix metalloproteinase (MMP) activity are responsible for the second phase of contraction. In parallel, we have started to develop a novel ex-vivo model of conjunctival tissue contraction, which completes and extends our 2-phase in vitro contraction model by using an intact tissue. The purpose of this project is to develop and validate these 2 new models as a more comprehensive an rationale approach to identify novel combinatorial strategies (i.e. targeting phase 1 and phase 2 of the contraction process) for the prevention and treatment of scarring.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-23</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-24</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>487593</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biosciences</gtr:department><gtr:description>Developing slow release drug-loaded microparticles for scarring prevention and therapy</gtr:description><gtr:id>5FCD8D2E-C544-4DDC-A6F2-497356BB0EE1</gtr:id><gtr:impact>Doxycyline loaded particles have been generated. Currently testing the biocompatibility in in vivo models (rat, rabbit)</gtr:impact><gtr:outcomeId>560a73efca7a47.45413498-1</gtr:outcomeId><gtr:partnerContribution>Dr Day is providing expertise on fabricating biodegradable Thermally Induced Phase Separation (TIPS) microspheres loaded with doxycycline to deliver adjuvant anti-scarring therapy at the time of surgery</gtr:partnerContribution><gtr:piContribution>our research team has developed the models to test the anti-scarring drugs</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>D259BC8E-4997-4CF7-A629-49524AA9385F</gtr:id><gtr:outcomeId>caNLDRAB9tb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fight For Sight Project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:fundingRef>1452/1453</gtr:fundingRef><gtr:id>48054B1D-14EA-4953-A74D-CB4E7F8DC177</gtr:id><gtr:outcomeId>JiB8TzPNsJ5</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Microarray expression profile in human Tenon's capsule fibroblasts during contraction in a standard in vitro contraction model using free floating collagen gels</gtr:description><gtr:id>5D24C7E5-C686-44CB-B79F-96FFDD893E14</gtr:id><gtr:impact>This database will be useful to further the research into contraction and fibrosis. It will be fully available upon publication of the paper describing the array, which we anticipate will be by the end of 2015. In the mean time, it is available upon request and we have publicized it in meetings (posters) and research seminars</gtr:impact><gtr:outcomeId>5500174ab963b8.05057115</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Fibroblast contraction expression array</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>primary ocular fibroblast cell lines with different contraction abilities</gtr:description><gtr:id>EA9DC8BF-E143-44D1-B481-B5AA46B734FB</gtr:id><gtr:impact>better resources to study ocular tissue contraction</gtr:impact><gtr:outcomeId>49D5314D089</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>primary ocular fibroblast cell lines</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have develop a more physiological model to study tissue contraction using ex-vivo maintained conjunctiva</gtr:description><gtr:id>D486D489-5AF2-4C17-BAAD-EB2210473466</gtr:id><gtr:impact>the model is now published (in press) and will be available for all to use. We already have developed it further to test novel anti-scarring drugs</gtr:impact><gtr:outcomeId>ckHFjr6GV1d</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ex-vivo model of conjunctival tissue contraction</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed a 3D model of adipogenesis for Thyroid Eye Disease that can be used to screen potential treatment as well as the effect of pressure on disease pathology.</gtr:description><gtr:id>DD09611A-A9FC-4062-A86E-59B8BB34EEA9</gtr:id><gtr:impact>This method has been published and we have started to collaborate with other researchers to develop the model in their labs (University of Cardiff)</gtr:impact><gtr:outcomeId>58aeef9766d2a8.09813966</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Physiological 3D model of adipogenesis and the influence of pressure in Thyroid Eye Disease</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D908BB1D-E0C4-46D2-8CF4-9556EA8E035F</gtr:id><gtr:title>Advancing the treatment of conjunctival scarring: a novel ex vivo model.</gtr:title><gtr:parentPublicationTitle>Archives of ophthalmology (Chicago, Ill. : 1960)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b847abee8ff432e1aa86afb9f5a4dec5"><gtr:id>b847abee8ff432e1aa86afb9f5a4dec5</gtr:id><gtr:otherNames>Tovell VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9950</gtr:issn><gtr:outcomeId>pm_13587_27_21555616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EA42305-110F-4A8A-86EE-052B7258189F</gtr:id><gtr:title>The effect of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is correlated to a decrease in cell protrusive activity.</gtr:title><gtr:parentPublicationTitle>European journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b3f6f15e5d4e5acf05d2d732064c30f"><gtr:id>9b3f6f15e5d4e5acf05d2d732064c30f</gtr:id><gtr:otherNames>Martin-Martin B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0171-9335</gtr:issn><gtr:outcomeId>ghc2GRNQ6vc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53DC6B8F-1FED-4953-8BEC-A8ADD8AAFC44</gtr:id><gtr:title>Assessment of solid microneedle rollers to enhance transmembrane delivery of doxycycline and inhibition of MMP activity.</gtr:title><gtr:parentPublicationTitle>Drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88279580b71427732b69ea752d26cb1b"><gtr:id>88279580b71427732b69ea752d26cb1b</gtr:id><gtr:otherNames>Omolu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1071-7544</gtr:issn><gtr:outcomeId>5aa278c7ce2a19.85894311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3738A081-4091-480B-ADCD-7D8CF07EB5A5</gtr:id><gtr:title>Stimulation of cortical myosin phosphorylation by p114RhoGEF drives cell migration and tumor cell invasion.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cdb984f500880bf778502106c859847"><gtr:id>0cdb984f500880bf778502106c859847</gtr:id><gtr:otherNames>Terry SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58aef642d7d296.57016540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3B824D5-6592-4F81-8613-4BEB00EB54E3</gtr:id><gtr:title>Rac1 inhibition prevents tissue contraction and MMP mediated matrix remodeling in the conjunctiva.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b847abee8ff432e1aa86afb9f5a4dec5"><gtr:id>b847abee8ff432e1aa86afb9f5a4dec5</gtr:id><gtr:otherNames>Tovell VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>pm_13587_27_22695959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECB1DA1A-C567-4C53-873A-B9A7D0181486</gtr:id><gtr:title>Independent adipogenic and contractile properties of fibroblasts in Graves' orbitopathy: an in vitro model for the evaluation of treatments.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e3e9b152d63bb3495d9a000cd75f74"><gtr:id>08e3e9b152d63bb3495d9a000cd75f74</gtr:id><gtr:otherNames>Li H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54609b1c517ec5.70993434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61E94289-028C-4DA6-92BB-96598665DD52</gtr:id><gtr:title>The role of the MRTF-A/SRF pathway in ocular fibrosis.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97b274883a1e43c32b7d3477aca9ca99"><gtr:id>97b274883a1e43c32b7d3477aca9ca99</gtr:id><gtr:otherNames>Yu-Wai-Man C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>54609b1c863227.56000376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD12F1F7-1620-4056-968E-F2E7F6A2982F</gtr:id><gtr:title>An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f667712487e80557c532d0d17a670f73"><gtr:id>f667712487e80557c532d0d17a670f73</gtr:id><gtr:otherNames>Mohamed-Ahmed AHA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>5aa279bab944d2.59297363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B3D6517-B1DA-44C4-ABA9-380113284236</gtr:id><gtr:title>Eyelid and Sternum Fibroblasts Differ in Their Contraction Potential and Responses to Inflammatory Cytokines.</gtr:title><gtr:parentPublicationTitle>Plastic and reconstructive surgery. Global open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e3e9b152d63bb3495d9a000cd75f74"><gtr:id>08e3e9b152d63bb3495d9a000cd75f74</gtr:id><gtr:otherNames>Li H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2169-7574</gtr:issn><gtr:outcomeId>560a6fe9694021.36185760</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801049</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>